EMA director still 'open-minded' on data disclosure policy
This article was originally published in SRA
Executive Summary
As the European Medicines Agency's management board prepares to examine the agency's controversial draft policy on clinical trial data disclosure at its meeting tomorrow, the EMA's executive director Guido Rasi has said he is willing to explore more "user-friendly" approaches to allay researchers' concerns over limitations on access to trial data1.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.